UK Markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.3728+0.0340 (+10.04%)
At close: 04:00PM EDT
0.4000 +0.03 (+7.30%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 34.3300
52-week low 30.3000
50-day moving average 30.7810
200-day moving average 32.1000

Share statistics

Avg vol (3-month) 311.39M
Avg vol (10-day) 38.89M
Shares outstanding 5174.96M
Implied shares outstanding 6N/A
Float 8179.2M
% held by insiders 11.16%
% held by institutions 153.92%
Shares short (28 Apr 2022) 419.12M
Short ratio (28 Apr 2022) 41.06
Short % of float (28 Apr 2022) 410.53%
Short % of shares outstanding (28 Apr 2022) 410.42%
Shares short (prior month 30 Mar 2022) 421.41M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin -132.43%
Operating margin (ttm)-106.81%

Management effectiveness

Return on assets (ttm)-24.38%
Return on equity (ttm)-174.55%

Income statement

Revenue (ttm)213.58M
Revenue per share (ttm)1.29
Quarterly revenue growth (yoy)5.10%
Gross profit (ttm)-17.92M
EBITDA -190.16M
Net income avi to common (ttm)-282.84M
Diluted EPS (ttm)-1.8870
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)149.8M
Total cash per share (mrq)0.83
Total debt (mrq)136.05M
Total debt/equity (mrq)177.94
Current ratio (mrq)1.06
Book value per share (mrq)0.79

Cash flow statement

Operating cash flow (ttm)-252.96M
Levered free cash flow (ttm)-141.62M